Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
COGT · Why this verdict
Why Cogent Biosciences (COGT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
All meaningful clinical value is concentrated in the bezuclastinib program, making the investment outcome binary — the success or failure of that single asset will largely determine shareholder returns with no other pipeline asset to cushion an adverse result. Bear case | A second distinct clinical program entering active development would meaningfully reduce the binary risk profile and broaden the pipeline's probability-weighted value. | →Stable |
| CounterDeep focus on a single program can accelerate development timelines and concentrate management expertise; the analyst community has assigned a consensus target implying 64% upside, suggesting the market assigns meaningful probability of success to this concentrated approach. | ||
The business is consuming cash with negative free cash flow and a quality score of 1.5 out of 10 — well below the minimum threshold of 4.0 — indicating the company has not yet built a financially self-sustaining operating model. Warnings | Free cash flow turning positive for 2 consecutive quarters would be the key signal that the burn-rate constraint has been resolved. | →Stable |
| CounterA current ratio of 5 indicates sufficient near-term liquidity, and a Piotroski F-Score of 4.4 out of 9 suggests the balance sheet has not yet reached a distress state — the company can sustain operations while awaiting catalysts. | ||
The stock trades roughly 42% below the consensus analyst target with a risk/reward ratio of approximately 6-to-1 in favor of the bull case — one of the widest favorable asymmetry profiles in the screen — and the asymmetry threshold has been cleared. Price targets | Meaningful positive clinical progress that narrows the gap to the analyst consensus target by more than 20 percentage points over the next 12 months. | →Stable |
| CounterAnalyst price targets for pre-commercial biotechs can reflect aspirational probability-weighted scenarios rather than near-term cash flow; a wide gap between current price and target may simply be the market's rational discount for binary clinical risk. | ||
Despite operating at a loss, the company has beaten analyst estimates on loss per share in three of the last four quarters — including the most recent period — suggesting management is controlling the cash burn trajectory more tightly than consensus expected. Earnings | Beat rate on EPS staying above 75% (at least 3 of 4 quarters) over the next year with loss per share narrowing year over year. | →Stable |
| CounterThe one miss — a -10.5% shortfall in the second-most-recent quarter — was notably large for a company where burn control is the primary operational metric, and the average surprise across all four quarters is near zero, limiting confidence in the streak's durability. | ||
All meaningful clinical value is concentrated in the bezuclastinib program, making the investment outcome binary — the success or failure of that single asset will largely determine shareholder returns with no other pipeline asset to cushion an adverse result.
→StableBear case
- Expectation
- A second distinct clinical program entering active development would meaningfully reduce the binary risk profile and broaden the pipeline's probability-weighted value.
CounterDeep focus on a single program can accelerate development timelines and concentrate management expertise; the analyst community has assigned a consensus target implying 64% upside, suggesting the market assigns meaningful probability of success to this concentrated approach.
The business is consuming cash with negative free cash flow and a quality score of 1.5 out of 10 — well below the minimum threshold of 4.0 — indicating the company has not yet built a financially self-sustaining operating model.
→StableWarnings
- Expectation
- Free cash flow turning positive for 2 consecutive quarters would be the key signal that the burn-rate constraint has been resolved.
CounterA current ratio of 5 indicates sufficient near-term liquidity, and a Piotroski F-Score of 4.4 out of 9 suggests the balance sheet has not yet reached a distress state — the company can sustain operations while awaiting catalysts.
The stock trades roughly 42% below the consensus analyst target with a risk/reward ratio of approximately 6-to-1 in favor of the bull case — one of the widest favorable asymmetry profiles in the screen — and the asymmetry threshold has been cleared.
→StablePrice targets
- Expectation
- Meaningful positive clinical progress that narrows the gap to the analyst consensus target by more than 20 percentage points over the next 12 months.
CounterAnalyst price targets for pre-commercial biotechs can reflect aspirational probability-weighted scenarios rather than near-term cash flow; a wide gap between current price and target may simply be the market's rational discount for binary clinical risk.
Despite operating at a loss, the company has beaten analyst estimates on loss per share in three of the last four quarters — including the most recent period — suggesting management is controlling the cash burn trajectory more tightly than consensus expected.
→StableEarnings
- Expectation
- Beat rate on EPS staying above 75% (at least 3 of 4 quarters) over the next year with loss per share narrowing year over year.
CounterThe one miss — a -10.5% shortfall in the second-most-recent quarter — was notably large for a company where burn control is the primary operational metric, and the average surprise across all four quarters is near zero, limiting confidence in the streak's durability.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Cogent Biosciences offers a favorable risk/reward ratio of roughly 6-to-1 and meaningful analyst-implied upside, but the business is cash-burning, quality falls far below the minimum acceptable threshold of 4.0, and nearly all clinical value is concentrated in a single pipeline program — the asymmetry exists without the quality foundation to support a position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 0.4 |
- ▸Overbought (RSI 95)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 5.0 |
| Price target | 9.0 |
- ▸LLM news sentiment: +0.60 (n=1)
- ▸Analyst upside: 38%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
2.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.5 |
| growth rank | 5.0 |
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.5 |
| support resistance | 0.7 |
| 52w position | 8.0 |
Risk (lower is worse)
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.0 |
| days to cover | 4.8 |
| volatility | 2.4 |
| put call | 9.5 |
| implied vol | 0.6 |
| beta | 10.0 |
| debt equity | 8.4 |
| news risk | 6.0 |
- ▸High IV: 76%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 2.8 |
| news activity | 5.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:4.7>=4.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.3<1.5@spot
Warning (1)
- MOMENTUM:4.7<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
1.31
Upside
+19.7%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeCatalyst-Driven — Earnings in 29d with 3/4 beat streak
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.5 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:1.3<1.5@spot.
The strongest dimensions are Value at 7.5, Sentiment at 7.2, and Risk (lower is worse) at 6.0; the weakest are Quality at 1.5, Peer rank at 2.6, and Technical at 3.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.31 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Program Binary Risk
Trip ifAt least 2 distinct clinical-stage programs are active simultaneously for at least 2 consecutive quarters, reducing pipeline concentration.
- P2Cash Burn Quality Below Floor
Trip ifFree cash flow rises above $0 for 2 consecutive quarters.
- P3Favorable Asymmetry Analyst Upside
Trip ifStock price rises above $47.20, indicating the analyst consensus upside gap has fully closed.
- P4Burn Rate Control Beat Streak
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.